Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

血漿分画の世界市場予測(~2024年)

◆タイトル:Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024
◆商品コード:PH-4477
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年3月28日
◆ページ数:297
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥615,850見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥724,850見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥888,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

血漿分画の世界市場は、2019年の254億米ドルから2024年には349億米ドルに達し、この期間中6.6%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、さまざまな治療分野における免疫グロブリンの使用の増加、血漿採取(および血漿採取センターの数)の増加、α1-アンチトリプシンの使用の増加などが考えられます。一方で、血漿生成物の高コスト、限られた保険償還、および遺伝子組み換え型血液製剤の代替品の出現により、市場の成長は抑制されると予想されます。当調査レポートでは、血漿分画の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、製品(IVIG、アルブミン、第VIII因子、フォン・ヴィレブランド因子、PCC、プロテアーゼ阻害剤)分析、用途(免疫、血液、クリティカルケア、リウマチ)分析、エンドユーザー(病院、診療所、学術機関) 分析、血漿分画の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Global plasma fractionation market is projected to grow at a CAGR of 6.6%.”The global plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.
“By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019.”
The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.
“Factor VIII will dominate the coagulation factor concentrates market in 2019.”
The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market.
“North America is expected to hold the largest share during the forecast period (2019–2024)”
North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.
A breakdown of supply-side primary participants is mentioned below:
• By Company Type: Tier 1–38%, Tier 2–21%, and Tier 3–41%
• By Designation: C-level–30%, Director Level–28%, Others–42%
• By Region: North America–35%, Europe–25%, Asia Pacific–20%, Latin America–12%, Middle East and Africa-8%
Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.
Reasons to buy this report:
From an insight perspective, this research report has focused on various levels of analysis—the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market

• Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market

• Market Development: Comprehensive information about lucrative emerging markets–the report analyzes the markets for plasma fractionation across regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 SCOPE OF THE STUDY 25
1.3.1 MARKETS COVERED 25
1.3.2 YEARS CONSIDERED FOR THE STUDY 26
1.4 CURRENCY 26
1.5 STAKEHOLDERS 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH APPROACH 27
2.1.1 SECONDARY SOURCES 28
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY SOURCES 29
2.1.2.1 Primary sources 29
2.1.2.2 Key data from primary sources 30
2.1.2.3 Key industry insights 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 BOTTOM-UP APPROACH 33
2.2.2 TOP-DOWN APPROACH 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.4 MARKET SHARE ESTIMATION 35
2.5 ASSUMPTIONS FOR THE STUDY 35
2.6 LIMITATIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 40
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 40
4.2 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET 41
4.3 PLASMA FRACTIONATION MARKET: REGIONAL MIX 42
4.4 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES 42

5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
5.2.1 MARKET DRIVERS 43
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 43
5.2.1.2 Rising geriatric population across the globe 46
5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin 46
5.2.1.4 Increase in plasma collection 47
5.2.2 MARKET RESTRAINTS 49
5.2.2.1 High cost and limited reimbursement 49
5.2.2.2 Emergence of recombinant alternatives 50
5.2.3 MARKET OPPORTUNITIES 50
5.2.3.1 Rising prevalence of bleeding disorders 50
5.2.4 MARKET CHALLENGES 51
5.2.4.1 Stringent government regulations 51
6 INDUSTRY INSIGHTS 52
6.1 INTRODUCTION 52
6.2 KEY INDUSTRY TRENDS 52
6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES 53
6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS 54
6.2.3 RISING ADOPTION OF SCIG 55
6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 55
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 55
6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS 58
6.3 PORTER’S FIVE FORCES 59
6.3.1 THREAT OF NEW ENTRANTS 59
6.3.2 THREAT OF SUBSTITUTES 60
6.3.3 BARGAINING POWER OF SUPPLIERS 60
6.3.4 BARGAINING POWER OF BUYERS 61
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 61
6.4 VENDOR BENCHMARKING 62
6.4.1 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET 62
6.4.2 NO. OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER 64
6.4.3 BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN 64
6.5 PRICING ANALYSIS 65

7 PLASMA FRACTIONATION MARKET, BY PRODUCT 66
7.1 INTRODUCTION 67
7.2 IMMUNOGLOBULINS 68
7.2.1 INTRAVENOUS IMMUNOGLOBULINS 70
7.2.1.1 IVIg holds the largest share of the immunoglobulins market 70
7.2.2 SUBCUTANEOUS IMMUNOGLOBULINS 73
7.2.2.1 Benefit of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market 73
7.2.3 OTHER IMMUNOGLOBULINS 75
7.3 COAGULATION FACTOR CONCENTRATES 79
7.3.1 FACTOR VIII 82
7.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market 82
7.3.2 FACTOR IX 85
7.3.2.1 Growth in the aging population and the rise in the number of hemophilic patients is expected to drive the growth in this market 85
7.3.3 VON WILLEBRAND FACTOR 88
7.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia 88
7.3.4 PROTHROMBIN COMPLEX CONCENTRATE 90
7.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment 90
7.3.5 FIBRINOGEN CONCENTRATES 92
7.3.5.1 Safety profile, accuracy, and speed of administration have supported the growth of the fibrinogen concentrates market 92
7.3.6 FACTOR XIII 93
7.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for Factor XIII 93
7.4 ALBUMIN 95
7.4.1 WIDE DEMAND FOR ALBUMIN AS AN ANTIOXIDANT AND VOLUME EXPANDER WILL DRIVER MARKET GROWTH 95
7.5 PROTEASE INHIBITORS 98
7.5.1 INCREASING GLOBAL DISEASE BURDEN WILL DRIVE DEMAND FOR PROTEASE INHIBITORS 98
7.6 OTHER PRODUCTS 100
8 PLASMA FRACTIONATION MARKET, BY APPLICATION 102
8.1 INTRODUCTION 103
8.2 NEUROLOGY 104
8.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE THIS MARKET 104
8.3 IMMUNOLOGY 107
8.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET 107

8.4 HEMATOLOGY 110
8.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS 110
8.5 CRITICAL CARE 113
8.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS 113
8.6 PULMONOLOGY 115
8.6.1 RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY 115
8.7 HEMATO-ONCOLOGY 117
8.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS IN HEMATO-ONCOLOGY 117
8.8 RHEUMATOLOGY 119
8.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY 119
8.9 OTHER APPLICATIONS 120
9 PLASMA FRACTIONATION MARKET, BY END USER 122
9.1 INTRODUCTION 123
9.2 HOSPITALS & CLINICS 124
9.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH 124
9.3 CLINICAL RESEARCH LABORATORIES 126
9.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE THE MARKET FOR CLINICAL RESEARCH LABORATORIES 126
9.4 ACADEMIC INSTITUTES 128
9.4.1 INCREASING BASIC MEDICAL RESEARCH ACTIVITIES AND GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES 128
10 PLASMA FRACTIONATION MARKET, BY REGION 130
10.1 INTRODUCTION 131
10.2 NORTH AMERICA 134
10.2.1 US 138
10.2.1.1 The US dominates the global plasma fractionation market 138
10.2.2 CANADA 142
10.2.2.1 Canada is one of the world’s highest per capita users of IVIg 142
10.3 EUROPE 146
10.3.1 GERMANY 152
10.3.1.1 Germany has the highest plasma fractionation capacity in Europe 152
10.3.2 FRANCE 156
10.3.2.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France 156

10.3.3 ITALY 159
10.3.3.1 Growth in the country’s geriatric population to drive the market for plasma fractionation 159
10.3.4 SPAIN 163
10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth 163
10.3.5 UK 166
10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK 166
10.3.6 REST OF EUROPE 170
10.4 ASIA PACIFIC 173
10.4.1 CHINA 178
10.4.1.1 Significant growth in the incidence of diseases such as hypoalbuminemia, liver cancer, and hepatitis B are driving the growth of plasma-derived products market in China 178
10.4.2 JAPAN 182
10.4.2.1 The rising geriatric population is expected to increase the prevalence of neurological disorders and hematological diseases in Japan in the coming years 182
10.4.3 AUSTRALIA 186
10.4.3.1 High production of plasma products and the growing demand for plasma products for the treatment of chronic disease to drive market growth 186
10.4.4 INDIA 191
10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth 191
10.4.5 VIETNAM 194
10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth 194
10.4.6 INDONESIA 198
10.4.6.1 Growing government initiatives to drive market growth 198
10.4.7 MALAYSIA 202
10.4.7.1 Growing healthcare awareness, increasing prevalence of bleeding disorders, and the rising geriatric population are the major factors driving market growth 202
10.4.8 REST OF ASIA PACIFIC 206
10.5 LATIN AMERICA 209
10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES, RISING GERIATRIC POPULATION, AND INCREASING INCIDENCE OF BLEEDING DISORDERS TO DRIVE MARKET GROWTH IN LATIN AMERICA 209
10.6 MIDDLE EAST & AFRICA 212
10.6.1 TURKEY 216
10.6.1.1 Turkey dominated the plasma fractionation market in the Middle East and Africa 216
10.6.2 SAUDI ARABIA 220
10.6.2.1 Rising use of immunoglobulins in neurology and immunology and the strengthening of healthcare infrastructure to drive market growth 220
10.6.3 EGYPT 224
10.6.3.1 Growing research on plasma and plasma derivatives and the increasing adoption of plasma products to drive market growth 224
10.6.4 UAE 228
10.6.4.1 Increasing incidence of bleeding disorders and growing government initiatives for healthcare infrastructure development to drive market growth 228
10.6.5 REST OF MIDDLE EAST AND AFRICA 231
11 COMPETITIVE LANDSCAPE 234
11.1 OVERVIEW 234
11.2 MARKET SHARE ANALYSIS 236
11.2.1 MARKET SHARE ANALYSIS, BY PRODUCT,2018 238
11.2.1.1 Immunoglobulin market, by key players 238
11.2.1.1.1 IVIG market, by key players 238
11.2.1.2 Coagulation factor market, by key players 239
11.2.1.2.1 Factor VIII market, by key players 239
11.2.1.3 Albumin market, by key players 240
11.2.2 MARKET SHARE ANALYSIS, BY REGION,2018 240
11.2.2.1 North America plasma fractionation market, by key players 240
11.2.2.1.1 US plasma fractionation market, by key players 241
11.2.2.2 Europe plasma fractionation market, by key players 241
11.3 COMPETITIVE LEADERSHIP MAPPING 242
11.3.1 VISIONARY LEADERS 242
11.3.2 INNOVATORS 242
11.3.3 DYNAMIC DIFFERENTIATORS 242
11.3.4 EMERGING COMPANIES 242
11.4 COMPETITIVE SCENARIO AND TRENDS 244
11.4.1 PRODUCT LAUNCHES/APPROVALS 244
11.4.2 EXPANSIONS 244
11.4.3 ACQUISITIONS 245
11.4.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS 246

12 COMPANY PROFILES 247
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 CSL 247
12.2 GRIFOLS 251
12.3 SHIRE 256
12.4 OCTAPHARMA 260
12.5 KEDRION 263
12.6 LFB 267
12.7 BIOTEST 270
12.8 SANQUIN 274
12.9 CHINA BIOLOGIC PRODUCTS 276
12.10 BIO PRODUCTS LABORATORY (BPL) 279
12.11 JAPAN BLOOD PRODUCTS ORGANIZATION 281
12.12 GC PHARMA (GREEN CROSS CORPORATION) 283
12.13 SHANGHAI RAAS BLOOD PRODUCTS 286
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 288
13.1 INSIGHTS OF INDUSTRY EXPERTS 288
13.2 DISCUSSION GUIDE 289
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 293
13.4 AVAILABLE CUSTOMIZATION 295
13.5 RELATED REPORT 295
13.6 AUTHOR DETAILS 296

LIST OF TABLES

TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS 43
TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG 44
TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017 45
TABLE 4 NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN
THE UK (2015-16) 45
TABLE 5 INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE 46
TABLE 6 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2018 49
TABLE 7 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2017 51
TABLE 8 INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS 52
TABLE 9 FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS 54
TABLE 10 PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014) 56
TABLE 11 CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2018 57
TABLE 12 MAJOR LOCAL PLAYERS IN CHINA 57
TABLE 13 REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON
PLASMA-DERIVED PRODUCTS 58
TABLE 14 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY PLAYER (2018) 65
TABLE 15 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY REGION (2018) 65
TABLE 16 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 67
TABLE 17 IVIG VS. SCIG THERAPY 68
TABLE 18 IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 69
TABLE 19 IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 20 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 71
TABLE 21 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 72
TABLE 22 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (METRIC TONS) 72
TABLE 23 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 73
TABLE 24 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 74
TABLE 25 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (METRIC TONS) 75
TABLE 26 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 76
TABLE 27 OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 78
TABLE 28 OTHER IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (MILLION INTERNATIONAL UNITS) 79
TABLE 29 COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 80
TABLE 30 COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 81
TABLE 31 FACTOR VIII OFFERED BY KEY MARKET PLAYERS 83
TABLE 32 FACTOR VIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 84
TABLE 33 FACTOR VIII MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS) 84
TABLE 34 FACTOR IX OFFERED BY KEY MARKET PLAYERS 86
TABLE 35 FACTOR IX MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 87
TABLE 36 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS 88
TABLE 37 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 89
TABLE 38 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS 90
TABLE 39 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 91
TABLE 40 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS 92
TABLE 41 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 93
TABLE 42 FACTOR XIII OFFERED BY KEY MARKET PLAYERS 94
TABLE 43 FACTOR XIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 94
TABLE 44 ALBUMIN OFFERED BY KEY MARKET PLAYERS 95
TABLE 45 ALBUMIN MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 97
TABLE 46 GLOBAL ALBUMIN MARKET, BY REGION, 2017–2024 (METRIC TONS) 97
TABLE 47 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS 98
TABLE 48 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 99
TABLE 49 OTHER PRODUCTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 101
TABLE 50 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 103
TABLE 51 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030 104
TABLE 52 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY 105
TABLE 53 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 106
TABLE 54 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY 107
TABLE 55 PRIMARY IMMUNODEFICIENCY DISEASE, BY TYPE 108
TABLE 56 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION,
2013 VS. 2015 108
TABLE 57 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY 109
TABLE 58 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 109
TABLE 59 NUMBER OF HEMOPHILIA PATIENTS (2012–2017) 110
TABLE 60 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY 112
TABLE 61 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 112
TABLE 62 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE 113
TABLE 63 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY,
2017–2024 (USD MILLION) 114
TABLE 64 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY 115
TABLE 65 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 116
TABLE 66 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA,
BY REGION, 2012 VS. 2015 VS. 2018 117
TABLE 67 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY 117
TABLE 68 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 118
TABLE 69 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 119
TABLE 70 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS 120
TABLE 71 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 121
TABLE 72 PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 123
TABLE 73 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2024 (USD MILLION) 125
TABLE 74 CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017) 126
TABLE 75 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES,
BY COUNTRY, 2017–2024 (USD MILLION) 127
TABLE 76 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION) 129
TABLE 77 REGIONAL DISTRIBUTION OF PLASMA FRACTIONATION PLANTS AND PLASMA THROUGHPUT, BY REGION, 2014 131
TABLE 78 PLASMA FRACTIONATION MARKET, BY REGION, 2017–2024 (USD MILLION) 133
TABLE 79 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017 134
TABLE 80 TRANSFER OF PLASMA FROM US TO OTHER REGIONS, 2014 134
TABLE 81 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 136
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 136
TABLE 83 NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 136
TABLE 84 NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 137
TABLE 85 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 137
TABLE 86 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 138
TABLE 87 US: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 140
TABLE 88 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 140
TABLE 89 US: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 140
TABLE 90 US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 141
TABLE 91 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 141
TABLE 92 US: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 142
TABLE 93 CANADA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 143
TABLE 94 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 143
TABLE 95 CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 144
TABLE 96 CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 144
TABLE 97 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 145
TABLE 98 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 145
TABLE 99 EUROPE: PLASMA COLLECTION, 2007–2016 146
TABLE 100 PLASMA FRACTIONATION PLANTS IN EUROPE (2017) 147
TABLE 101 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 149
TABLE 102 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 149
TABLE 103 EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 104 EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 150
TABLE 105 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 151
TABLE 106 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 151
TABLE 107 GERMANY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 153
TABLE 108 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 153
TABLE 109 GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 154
TABLE 110 GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 154
TABLE 111 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 155
TABLE 112 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 155
TABLE 113 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2017 156
TABLE 114 FRANCE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 157
TABLE 115 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 157
TABLE 116 FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 157
TABLE 117 FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 158
TABLE 118 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 158
TABLE 119 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 159
TABLE 120 ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013 159
TABLE 121 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E) 160
TABLE 122 ITALY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 160
TABLE 123 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 161
TABLE 124 ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 161
TABLE 125 ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 161
TABLE 126 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 162
TABLE 127 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 162
TABLE 128 SPAIN: KEY MACROINDICATORS FOR THE PLASMS FRACTIONATION MARKET 163
TABLE 129 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 164
TABLE 130 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 164
TABLE 131 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 164
TABLE 132 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 165
TABLE 133 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 165
TABLE 134 USAGE OF IMMUNOGLOBULINS 166
TABLE 135 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS
IN THE UK, 2012–2016 167
TABLE 136 VOLUME OF IMMUNOGLOBULINS USED FOR THE TOP 5 DIAGNOSES (2016) 167
TABLE 137 UK: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 168
TABLE 138 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 168
TABLE 139 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 168
TABLE 140 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 169
TABLE 141 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 169
TABLE 142 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 170
TABLE 143 TOTAL NUMBER OF HEMOPHILIA PATIENTS IN REST OF EUROPE: 2012–2017 171
TABLE 144 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 171
TABLE 145 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 172
TABLE 146 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 172
TABLE 147 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 173
TABLE 148 ROE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 173
TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 175
TABLE 150 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 175
TABLE 151 ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 176
TABLE 152 ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 176
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 177
TABLE 154 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 177
TABLE 155 CHINA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 179
TABLE 156 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 179
TABLE 157 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 180
TABLE 158 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 180
TABLE 159 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 181
TABLE 160 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 181
TABLE 161 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2017
(IN IU/TOTAL POPULATION) 182
TABLE 162 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2017 182
TABLE 163 JAPAN: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 183
TABLE 164 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 183
TABLE 165 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 184
TABLE 166 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 184
TABLE 167 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 185
TABLE 168 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 185
TABLE 169 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2006–2015 186
TABLE 170 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2017 (USD MILLION) 187
TABLE 171 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017) 188
TABLE 172 AUSTRALIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 188
TABLE 173 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 188
TABLE 174 AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 189
TABLE 175 AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 189
TABLE 176 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 190
TABLE 177 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 190
TABLE 178 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2016 191
TABLE 179 INDIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 192
TABLE 180 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 192
TABLE 181 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 192
TABLE 182 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 193
TABLE 183 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 193
TABLE 184 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 194
TABLE 185 VIETNAM: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 196
TABLE 186 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 196
TABLE 187 VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 196
TABLE 188 VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 197
TABLE 189 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 197
TABLE 190 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 198
TABLE 191 INDONESIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 200
TABLE 192 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 200
TABLE 193 INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 200
TABLE 194 INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 201
TABLE 195 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 201
TABLE 196 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 202
TABLE 197 MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS,
2012–2017 203
TABLE 198 MALAYSIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 203
TABLE 199 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 203
TABLE 200 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 204
TABLE 201 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 204
TABLE 202 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 205
TABLE 203 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 205
TABLE 204 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 206
TABLE 205 REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 207
TABLE 206 REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 207
TABLE 207 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 208
TABLE 208 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 208
TABLE 209 BRAZIL: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 209
TABLE 210 MEXICO: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 210
TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 210
TABLE 212 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 210
TABLE 213 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 211
TABLE 214 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 211
TABLE 215 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 212
TABLE 216 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, 2012–2017 212
TABLE 217 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2017 213
TABLE 218 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 213
TABLE 219 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 214
TABLE 220 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 214
TABLE 221 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 215
TABLE 222 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 215
TABLE 223 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 216
TABLE 224 TURKEY: DEMOGRAPHIC INDICATORS 216
TABLE 225 TURKEY: REPORTED CASES OF BLOOD DISORDERS, 2012 VS. 2014 217
TABLE 226 TURKEY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 217
TABLE 227 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 218
TABLE 228 TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 218
TABLE 229 TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 218
TABLE 230 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 219
TABLE 231 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 219
TABLE 232 ESTIMATED INCIDENCE AND PREVALENCE OF CID, SCID, AND MHC II DEFICIENCY IN CHILDREN IN SAUDI ARABIA 220
TABLE 233 PER CAPITA CONSUMPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND ALBUMIN (2015/2016) 221
TABLE 234 SAUDI ARABIA: BLOOD DISORDER CASES, BY TYPE, 2014 VS. 2016 221
TABLE 235 SAUDI ARABIA: KEY MACROINDICATORS FOR THE PLASMA
FRACTIONATION MARKET 221
TABLE 236 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 222
TABLE 237 SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 222
TABLE 238 SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 222
TABLE 239 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 223
TABLE 240 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 223
TABLE 241 EGYPT: BLOOD DISORDER CASES, BY TYPE, 2014–2017 224
TABLE 242 EGYPT: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 225
TABLE 243 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 225
TABLE 244 EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 226
TABLE 245 EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 226
TABLE 246 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 227
TABLE 247 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 227
TABLE 248 UAE: GROWTH IN THE NUMBER OF BLOOD DONORS 228
TABLE 249 UAE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 228
TABLE 250 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 229
TABLE 251 UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 229
TABLE 252 UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 229
TABLE 253 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 230
TABLE 254 UAE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 230
TABLE 255 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA,
2012 VS. 2017 231
TABLE 256 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII IN SOUTH AFRICA AND QATAR (IU/TOTAL POPULATION), 2013 VS. 2017 231
TABLE 257 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 232
TABLE 258 ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 232
TABLE 259 ROMEA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 232
TABLE 260 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 233
TABLE 261 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 233
TABLE 262 GROWTH STRATEGY MATRIX 236
TABLE 263 PRODUCT LAUNCHES/APPROVALS, JANUARY 2016 TO APRIL 2019 244
TABLE 264 EXPANSIONS, JANUARY 2016 TO APRIL 2019 244
TABLE 265 ACQUISITIONS, JANUARY 2016 TO APRIL 2019 245
TABLE 266 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2016 TO APRIL 2019 246


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 27
FIGURE 2 SUPPLY SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 31
FIGURE 3 DEMAND SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 32
FIGURE 4 DATA TRIANGULATION METHODOLOGY 34
FIGURE 5 IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, FROM 2019 TO 2024 36
FIGURE 6 NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 37
FIGURE 7 PLASMA FRACTIONATION MARKET, BY END USER, 2019 VS. 2024 (USD MILLION) 37
FIGURE 8 GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2018 38
FIGURE 9 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH 40
FIGURE 10 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2018 41
FIGURE 11 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 42
FIGURE 12 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD 42
FIGURE 13 GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030 47
FIGURE 14 SOURCE PLASMA COLLECTION IN THE US, 2004–2017 48
FIGURE 15 PLASMA COLLECTION CENTERS IN THE US AND EUROPE, 2007–2016 48
FIGURE 16 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE,
2012–2017 50
FIGURE 17 PLASMA FRACTIONATION MARKET IN CHINA VS. US, 2017–2024 56
FIGURE 18 PORTER’S FIVE FORCES ANALYSIS 59
FIGURE 19 IMMUNOGLOBULIN SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024 67
FIGURE 20 PREVALENCE OF BLEEDING DISORDERS, BY COUNTRY, 2017 80
FIGURE 21 MEAN PER CAPITA USAGE OF FACTOR VIII (2016 VS 2017) 82
FIGURE 22 MEAN PER CAPITA USAGE OF FACTOR IX (2016 VS 2017) 85
FIGURE 23 NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024 103
FIGURE 24 NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016 VS. 2017 111
FIGURE 25 HOSPITALS & CLINICS TO REGISTER THE HIGHEST CAGR DURING
THE FORECAST PERIOD 123
FIGURE 26 NORTH AMERICA TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 132
FIGURE 27 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 133
FIGURE 28 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT 135
FIGURE 29 PLASMA COLLECTION VOLUME IN THE US, 2004–2017 138
FIGURE 30 PLASMA COLLECTION CENTERS IN THE US, 2005–2017 139
FIGURE 31 EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT 148
FIGURE 32 HEMOPHILIA A & B PATIENTS IN GERMANY, 2013–2016 152
FIGURE 33 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT 174
FIGURE 34 FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008–2017 (USD MILLION) 187
FIGURE 35 MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM, 2014–2017 (IU/POPULATION) 195
FIGURE 36 PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS IN VIETNAM, 2014–2017 195
FIGURE 37 BLOOD DONATION IN INDONESIA, 2011–2015 (MILLION UNITS) 199
FIGURE 38 KEY STRATEGIES ADOPTED BY PLAYERS (JANUARY 2016 TO APRIL 2019) 235
FIGURE 39 PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 236
FIGURE 40 COMPETITIVE LEADERSHIP MAPPING 243
FIGURE 41 CSL: COMPANY SNAPSHOT (2018) 247
FIGURE 42 GRIFOLS: COMPANY SNAPSHOT (2017) 251
FIGURE 43 SHIRE: COMPANY SNAPSHOT (2017) 256
FIGURE 44 OCTAPHARMA: COMPANY SNAPSHOT (2018) 260
FIGURE 45 KEDRION: COMPANY SNAPSHOT (2017) 263
FIGURE 46 LFB: COMPANY SNAPSHOT (2016) 267
FIGURE 47 BIOTEST: COMPANY SNAPSHOT (2017) 270
FIGURE 48 SANQUIN: COMPANY SNAPSHOT (2017) 274
FIGURE 49 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2017) 276
FIGURE 50 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016) 281
FIGURE 51 GC PHARMA: COMPANY SNAPSHOT (2017) 283


★調査レポート[血漿分画の世界市場予測(~2024年)] ( Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024 / PH-4477) 販売に関する免責事項
[血漿分画の世界市場予測(~2024年)] ( Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024 / PH-4477) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆